Company intelligence / Profile preview
Rona Therapeutics
Shanghai, Shanghai, Chinaronatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Rona’s lead program RN1871—an siRNA targeting angiotensinogen (AGT) for hypertension—received IND approval from China’s NMPA in April 2025. Preclinical data showed potent AGT suppression with significant blood pressure reduction and a favorable safety profile. Phase I trials are planned to assess safety/pharmacokinetics/efficacy in humans. The company has additional preclinical programs targeting cardiometabolic, obesity/MASH, and neurological indications using its proprietary siRNA platforms.
- Therapeutic areas
- GastroenterologyCardiovascularEndocrinologyNeurology
- Modalities
- siRNA (small interfering RNA)Modular and programmable RNA medicinesOligonucleotide therapeutics
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
Sanofi – partnership to expand Rona’s siRNA portfolio in both liver and non-liver applications announced July 2022.
Beyond the preview
Go deeper on Rona Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rona Therapeutics.